ARMO Biosciences, which is developing immunotherapies targeting various cancers and solid tumors, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The Redwood City, CA-based company was founded in 2012 and plans to list on the Nasdaq under the symbol ARMO. ARMO Biosciences filed confidentially on January 18, 2017. Jefferies, Leerink Partners and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
